{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,28]],"date-time":"2026-08-28T03:18:59Z","timestamp":1787887139086,"version":"build-2784847793"},"reference-count":36,"publisher":"Springer Science and Business Media LLC","issue":"2","license":[{"start":{"date-parts":[[2025,1,3]],"date-time":"2025-01-03T00:00:00Z","timestamp":1735862400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2025,1,3]],"date-time":"2025-01-03T00:00:00Z","timestamp":1735862400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Cancer Immunol Immunother"],"DOI":"10.1007\/s00262-024-03905-0","type":"journal-article","created":{"date-parts":[[2025,1,3]],"date-time":"2025-01-03T05:15:05Z","timestamp":1735881305000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":6,"title":["Metastatic sites of baseline as predictors in recurrent or metastatic nasopharyngeal carinoma treated with PD-L1 inhibitor: a secondary analysis of multicenter, single-arm, phase II study (KL-A167)"],"prefix":"10.1007","volume":"74","author":[{"given":"Yuantai","family":"Li","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yu","family":"Min","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhigong","family":"Wei","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zheran","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yiyan","family":"Pei","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yujie","family":"Yang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kun","family":"Gao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ge","family":"Song","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shihong","family":"Xu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shuangshuang","family":"He","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Junyou","family":"Ge","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yan","family":"Qing","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Youneng","family":"Wei","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ping","family":"Ai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ye","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xingchen","family":"Peng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,1,3]]},"reference":[{"key":"3905_CR1","doi-asserted-by":"publisher","first-page":"64","DOI":"10.1016\/S0140-6736(19)30956-0","volume":"394","author":"Y-P Chen","year":"2019","unstructured":"Chen Y-P et al (2019) Nasopharyngeal carcinoma. The Lancet 394:64\u201380","journal-title":"The Lancet"},{"key":"3905_CR2","doi-asserted-by":"publisher","first-page":"679","DOI":"10.1038\/s41571-021-00524-x","volume":"18","author":"KCW Wong","year":"2021","unstructured":"Wong KCW et al (2021) Nasopharyngeal carcinoma: an evolving paradigm. Nat Rev Clin Oncol 18:679\u2013695","journal-title":"Nat Rev Clin Oncol"},{"key":"3905_CR3","first-page":"115","volume":"66","author":"W Chen","year":"2016","unstructured":"Chen W et al (2016) Cancer statistics in China, 2015. CA Cancer J Clin 66:115\u2013132","journal-title":"CA Cancer J Clin"},{"key":"3905_CR4","doi-asserted-by":"publisher","first-page":"41","DOI":"10.1186\/s40880-016-0103-5","volume":"35","author":"H-Y Wang","year":"2016","unstructured":"Wang H-Y et al (2016) A new prognostic histopathologic classification of nasopharyngeal carcinoma. Chin J Cancer 35:41","journal-title":"Chin J Cancer"},{"key":"3905_CR5","volume":"31","author":"Y Shi","year":"2023","unstructured":"Shi Y et al (2023) Efficacy and safety of KL-A167 in previously treated recurrent or metastatic nasopharyngeal carcinoma: a multicenter, single-arm, phase 2 study. Lancet Reg Health West Pac 31:100617","journal-title":"Lancet Reg Health West Pac"},{"key":"3905_CR6","doi-asserted-by":"publisher","first-page":"3356","DOI":"10.1200\/JCO.2015.60.9347","volume":"33","author":"AWM Lee","year":"2015","unstructured":"Lee AWM, Ma BBY, Ng WT, Chan ATC (2015) Management of nasopharyngeal carcinoma: current practice and future perspective. J Clin Oncol 33:3356\u20133364","journal-title":"J Clin Oncol"},{"key":"3905_CR7","doi-asserted-by":"publisher","first-page":"3273","DOI":"10.1200\/JCO.21.00396","volume":"39","author":"S Hong","year":"2021","unstructured":"Hong S et al (2021) Gemcitabine plus cisplatin versus fluorouracil plus cisplatin as first-line therapy for recurrent or metastatic nasopharyngeal carcinoma: final overall survival Analysis of GEM20110714 phase III study. J Clin Oncol 39:3273\u20133282","journal-title":"J Clin Oncol"},{"key":"3905_CR8","doi-asserted-by":"publisher","first-page":"175883592210962","DOI":"10.1177\/17588359221096214","volume":"14","author":"J-Y Xu","year":"2022","unstructured":"Xu J-Y, Wei X-L, Wang Y-Q, Wang F-H (2022) Current status and advances of immunotherapy in nasopharyngeal carcinoma. Ther Adv Med Oncol 14:175883592210962","journal-title":"Ther Adv Med Oncol"},{"key":"3905_CR9","doi-asserted-by":"publisher","first-page":"2305","DOI":"10.1002\/ijc.32869","volume":"146","author":"L Masterson","year":"2020","unstructured":"Masterson L et al (2020) Immune checkpoint inhibitors in advanced nasopharyngeal carcinoma: beyond an era of chemoradiation? Int J Cancer 146:2305\u20132314","journal-title":"Int J Cancer"},{"key":"3905_CR10","first-page":"239","volume":"29","author":"C Feng","year":"2021","unstructured":"Feng C et al (2021) The prognostic significance of APOBEC3B and PD-L1\/PD-1 in nasopharyngeal carcinoma. Appl Immunohistochem Mol Morphol AIMM 29:239\u2013244","journal-title":"Appl Immunohistochem Mol Morphol AIMM"},{"key":"3905_CR11","doi-asserted-by":"publisher","first-page":"5","DOI":"10.1158\/1078-0432.CCR-21-1193","volume":"28","author":"JC Lee","year":"2022","unstructured":"Lee JC et al (2022) The liver-immunity nexus and cancer immunotherapy. Clin Cancer Res 28:5\u201312","journal-title":"Clin Cancer Res"},{"key":"3905_CR12","first-page":"1045","volume":"26","author":"S Sumodhee","year":"2022","unstructured":"Sumodhee S et al (2022) Impact of radiotherapy schedule on survival of patients treated with immune-checkpoint inhibitors for advanced melanoma and non-small cell lung cancer. cancer radiother. J Soc Franc Radio Oncol. 26:1045\u20131053","journal-title":"J Soc Franc Radio Oncol."},{"key":"3905_CR13","doi-asserted-by":"publisher","first-page":"2203699","DOI":"10.1002\/advs.202203699","volume":"10","author":"Y Zou","year":"2023","unstructured":"Zou Y et al (2023) The single-cell landscape of intratumoral heterogeneity and the immunosuppressive microenvironment in liver and brain metastases of breast cancer. Adv Sci 10:2203699","journal-title":"Adv Sci"},{"key":"3905_CR14","doi-asserted-by":"publisher","first-page":"86","DOI":"10.1002\/cncr.32522","volume":"126","author":"I Pires Da Silva","year":"2020","unstructured":"Pires Da Silva I et al (2020) Site-specific response patterns, pseudoprogression, and acquired resistance in patients with melanoma treated with ipilimumab combined with anti\u2013PD-1 therapy. Cancer 126:86\u201397","journal-title":"Cancer"},{"key":"3905_CR15","doi-asserted-by":"publisher","first-page":"857","DOI":"10.1186\/s12885-019-6073-7","volume":"19","author":"MA Bilen","year":"2019","unstructured":"Bilen MA et al (2019) Sites of metastasis and association with clinical outcome in advanced stage cancer patients treated with immunotherapy. BMC Cancer 19:857","journal-title":"BMC Cancer"},{"key":"3905_CR16","doi-asserted-by":"publisher","DOI":"10.1136\/jitc-2020-002014","volume":"9","author":"Y Ma","year":"2021","unstructured":"Ma Y et al (2021) Copy number loss in granzyme genes confers resistance to immune checkpoint inhibitor in nasopharyngeal carcinoma. J Immunother Cancer 9:e002014","journal-title":"J Immunother Cancer"},{"key":"3905_CR17","doi-asserted-by":"publisher","first-page":"4050","DOI":"10.1200\/JCO.2017.73.3675","volume":"35","author":"C Hsu","year":"2017","unstructured":"Hsu C et al (2017) Safety and antitumor activity of pembrolizumab in patients with programmed death-ligand 1\u2013positive nasopharyngeal carcinoma: results of the KEYNOTE-028 study. J Clin Oncol 35:4050\u20134056","journal-title":"J Clin Oncol"},{"key":"3905_CR18","doi-asserted-by":"publisher","first-page":"1411","DOI":"10.1001\/jamaoncol.2019.2187","volume":"5","author":"SL Topalian","year":"2019","unstructured":"Topalian SL et al (2019) Five-year survival and correlates among patients with advanced melanoma, renal cell Carcinoma, or non-small cell lung cancer treated with nivolumab. JAMA Oncol 5:1411","journal-title":"JAMA Oncol"},{"key":"3905_CR19","doi-asserted-by":"publisher","first-page":"417","DOI":"10.1158\/2326-6066.CIR-16-0325","volume":"5","author":"PC Tumeh","year":"2017","unstructured":"Tumeh PC et al (2017) Liver metastasis and treatment outcome with Anti-PD-1 monoclonal antibody in patients with melanoma and NSCLC. Cancer Immunol Res 5:417\u2013424","journal-title":"Cancer Immunol Res"},{"key":"3905_CR20","doi-asserted-by":"publisher","first-page":"568","DOI":"10.1038\/nature13954","volume":"515","author":"PC Tumeh","year":"2014","unstructured":"Tumeh PC et al (2014) PD-1 blockade induces responses by inhibiting adaptive immune resistance. Nature 515:568\u2013571","journal-title":"Nature"},{"key":"3905_CR21","doi-asserted-by":"publisher","first-page":"86","DOI":"10.1002\/cncr.32522","volume":"126","author":"I Pires Da Silva","year":"2020","unstructured":"Pires Da Silva I et al (2020) Site-specific response patterns, pseudoprogression, and acquired resistance in patients with melanoma treated with ipilimumab combined with anti \u2013PD-1 therapy. Cancer. 126:86\u201397","journal-title":"Cancer."},{"key":"3905_CR22","doi-asserted-by":"publisher","first-page":"34","DOI":"10.21037\/atm-20-1471","volume":"9","author":"M Qiao","year":"2021","unstructured":"Qiao M et al (2021) Efficacy of immune-checkpoint inhibitors in advanced non-small cell lung cancer patients with different metastases. Ann Transl Med 9:34\u201334","journal-title":"Ann Transl Med"},{"key":"3905_CR23","doi-asserted-by":"publisher","first-page":"1081","DOI":"10.2217\/imt.12.99","volume":"4","author":"G Mazzolini","year":"2012","unstructured":"Mazzolini G, Ochoa MC, Morales-Kastresana A, Sanmamed MF, Melero I (2012) The liver, liver metastasis and liver cancer: a special case for immunotherapy with cytokines and immunostimulatory monoclonal antibodies. Immunotherapy 4:1081\u20131085","journal-title":"Immunotherapy"},{"key":"3905_CR24","doi-asserted-by":"publisher","first-page":"764","DOI":"10.1002\/ca.22350","volume":"27","author":"RM Juza","year":"2014","unstructured":"Juza RM, Pauli EM (2014) Clinical and surgical anatomy of the liver: a review for clinicians. Clin Anat 27:764\u2013769","journal-title":"Clin Anat"},{"key":"3905_CR25","doi-asserted-by":"publisher","first-page":"887","DOI":"10.1126\/science.abg4864","volume":"371","author":"ER Andersson","year":"2021","unstructured":"Andersson ER (2021) In the zone for liver proliferation. Science 371:887\u2013888","journal-title":"Science"},{"key":"3905_CR26","doi-asserted-by":"publisher","first-page":"152","DOI":"10.1038\/s41591-020-1131-x","volume":"27","author":"J Yu","year":"2021","unstructured":"Yu J et al (2021) Liver metastasis restrains immunotherapy efficacy via macrophage-mediated T cell elimination. Nat Med 27:152\u2013164","journal-title":"Nat Med"},{"key":"3905_CR27","doi-asserted-by":"publisher","first-page":"1550","DOI":"10.1038\/s41591-018-0136-1","volume":"24","author":"P Jiang","year":"2018","unstructured":"Jiang P et al (2018) Signatures of T cell dysfunction and exclusion predict cancer immunotherapy response. Nat Med 24:1550\u20131558","journal-title":"Nat Med"},{"key":"3905_CR28","doi-asserted-by":"publisher","first-page":"2904","DOI":"10.1158\/0008-5472.CAN-21-4141","volume":"82","author":"L Jenkins","year":"2022","unstructured":"Jenkins L et al (2022) Cancer-associated fibroblasts suppress cd8+ t-cell infiltration and confer resistance to immune-checkpoint blockade. Cancer Res 82:2904\u20132917","journal-title":"Cancer Res"},{"key":"3905_CR29","doi-asserted-by":"publisher","first-page":"e601","DOI":"10.1016\/j.cllc.2019.06.020","volume":"20","author":"S Sridhar","year":"2019","unstructured":"Sridhar S et al (2019) Prognostic significance of liver metastasis in durvalumab-treated lung cancer patients. Clin Lung Cancer 20:e601\u2013e608","journal-title":"Clin Lung Cancer"},{"key":"3905_CR30","doi-asserted-by":"publisher","first-page":"1173","DOI":"10.1097\/JU.0000000000001199","volume":"204","author":"G Sonpavde","year":"2020","unstructured":"Sonpavde G et al (2020) Five-factor prognostic model for survival of post-platinum patients with metastatic urothelial carcinoma receiving PD-L1 Inhibitors. J Urol 204:1173\u20131179","journal-title":"J Urol"},{"key":"3905_CR31","doi-asserted-by":"publisher","first-page":"1278","DOI":"10.1080\/21645515.2020.1823779","volume":"17","author":"Y Huang","year":"2021","unstructured":"Huang Y et al (2021) Metastatic sites as predictors in advanced NSCLC treated with PD-1 inhibitors: a systematic review and meta-analysis. Hum Vaccines Immunother 17:1278\u20131287","journal-title":"Hum Vaccines Immunother"},{"key":"3905_CR32","doi-asserted-by":"publisher","first-page":"E37","DOI":"10.1002\/hed.24099","volume":"38","author":"SJM Lim","year":"2016","unstructured":"Lim SJM et al (2016) Metastasectomy for metachronous pulmonary and hepatic metastases from nasopharyngeal carcinoma: report of 6 cases and review of the literature: resection of pulmonary and hepatic metastases from NPC. Head Neck 38:E37\u2013E40","journal-title":"Head Neck"},{"key":"3905_CR33","doi-asserted-by":"publisher","first-page":"818","DOI":"10.1186\/1471-2407-14-818","volume":"14","author":"J Huang","year":"2014","unstructured":"Huang J et al (2014) Partial hepatectomy for liver metastases from nasopharyngeal carcinoma: a comparative study and review of the literature. BMC Cancer 14:818","journal-title":"BMC Cancer"},{"key":"3905_CR34","doi-asserted-by":"publisher","first-page":"1069010","DOI":"10.3389\/fimmu.2023.1069010","volume":"14","author":"G-Y Liu","year":"2023","unstructured":"Liu G-Y et al (2023) Development of a prognostic model to identify the metastatic nasopharyngeal carcinoma patients who may benefit from chemotherapy combination PD-1 inhibitor. Front Immunol 14:1069010","journal-title":"Front Immunol"},{"key":"3905_CR35","doi-asserted-by":"publisher","first-page":"6047","DOI":"10.1073\/pnas.1920413117","volume":"117","author":"D Hermans","year":"2020","unstructured":"Hermans D et al (2020) Lactate dehydrogenase inhibition synergizes with IL-21 to promote CD8 + T cell stemness and antitumor immunity. Proc Natl Acad Sci 117:6047\u20136055","journal-title":"Proc Natl Acad Sci"},{"key":"3905_CR36","doi-asserted-by":"publisher","first-page":"46","DOI":"10.1186\/s40425-018-0361-7","volume":"6","author":"J Gong","year":"2018","unstructured":"Gong J, Le TQ, Massarelli E, Hendifar AE, Tuli R (2018) Radiation therapy and PD-1\/PD-L1 blockade: the clinical development of an evolving anticancer combination. J Immunother Cancer 6:46","journal-title":"J Immunother Cancer"}],"updated-by":[{"DOI":"10.1007\/s00262-025-04162-5","type":"correction","label":"Correction","source":"publisher","updated":{"date-parts":[[2025,9,29]],"date-time":"2025-09-29T00:00:00Z","timestamp":1759104000000}}],"container-title":["Cancer Immunology, Immunotherapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00262-024-03905-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00262-024-03905-0\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00262-024-03905-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,9,29]],"date-time":"2025-09-29T07:14:49Z","timestamp":1759130089000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00262-024-03905-0"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,1,3]]},"references-count":36,"journal-issue":{"issue":"2","published-online":{"date-parts":[[2025,2]]}},"alternative-id":["3905"],"URL":"https:\/\/doi.org\/10.1007\/s00262-024-03905-0","relation":{},"ISSN":["1432-0851"],"issn-type":[{"value":"1432-0851","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,1,3]]},"assertion":[{"value":"10 July 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"25 November 2024","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"3 January 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"29 September 2025","order":4,"name":"change_date","label":"Change Date","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Correction","order":5,"name":"change_type","label":"Change Type","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"A Correction to this paper has been published:","order":6,"name":"change_details","label":"Change Details","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"https:\/\/doi.org\/10.1007\/s00262-025-04162-5","URL":"https:\/\/doi.org\/10.1007\/s00262-025-04162-5","order":7,"name":"change_details","label":"Change Details","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no competing interests.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of Interest"}}],"article-number":"72"}}